Seth Rudnick, M.D.
Dr. Rudnick has extensive expertise in drug discovery and development and healthcare investments. Dr. Rudnick is retired from Canaan Partners, where he built the global venture capital firm’s capability in biopharmaceutical investing. Prior to joining Canaan Partners, Dr. Rudnick served as Chief Executive Officer and Chairman of CytoTherapeutics, a company developing stem cell-based therapies to combat chronic diseases. He also helped found and served as the Head of Research and Development for Ortho Biotech, a division of Johnson & Johnson that provides life-improving products to individuals with a focus on cancer and chronic illnesses. He is a Clinical Adjunct Professor of Medicine at University of North Carolina, Chapel Hill, teaching and advising faculty members on biotechnology issues. Dr. Rudnick also serves on the Board of Directors for Aralez Pharmaceuticals Inc. and G1 Therapeutics.
Chief Executive Officer
Mr. Fowler joined Liquidia in 2008 after seven years in an executive leadership role at Johnson & Johnson (J&J). While at J&J, he served as President of Centocor, Inc., a multi-billion-dollar subsidiary focused on the development and commercialization of industry-leading biomedicines used to treat chronic inflammatory diseases. At Centocor, Mr. Fowler prepared the company for commercial product launches and continued the company’s legacy of double-digit growth for its flagship product REMICADE® (infliximab). Prior to Centocor, Mr. Fowler served as President of Ortho-McNeil Neurologics Inc. and Vice President of the central nervous system franchise at Ortho-McNeil Pharmaceuticals. He also had a successful 13-year career at Eli Lilly and Company where he held a variety of sales, marketing and business development roles with increasing responsibilities in the pharmaceutical and medical device divisions. Mr. Fowler received a B.S. in Pharmacy and an MBA from the University of North Carolina at Chapel Hill (UNC-CH).
Dr. Bloch is a General Partner at Canaan Partners. As an early investor and chairman, Dr. Bloch helped Advanced BioHealing (ABH), a leader in regenerative medicine, grow from a seed-stage company to a $750 million all-cash acquisition by Shire, generating a 15 times return for Canaan. He currently serves on the boards of companies in healthcare IT (Truveris and Ambra Health); biopharma (Envisia and Liquidia); medical devices (Mitraspan); and diagnostics (Sample6). Before joining Canaan in 2002, Dr. Bloch founded multiple start-ups, including Radiology Management Sciences (RMS), a pioneer in managing radiology benefits for health plans, where he was CEO for 6 years. Dr. Bloch obtained his AB from Dartmouth College, received his MA in the history of science and public policy from Harvard, and he earned his medical degree from the University of Rochester. Dr. Bloch received his medical training at Massachusetts General Hospital/Harvard Medical School (radiology) and Lenox Hill Hospital/Cornell Medical School (internal medicine). It was there that he contracted the entrepreneurial bug – the one thing he admits he can’t cure.
Dr. Cheng of Morningside Venture Investments Limited focuses on life science and technology investments. Prior to joining Morningside, Dr. Cheng was Director of Research and Development at Serica Technologies, a Morningside portfolio company. In addition, Dr. Cheng was previously an Associate Director at Novartis Pharmaceuticals in Clinical Development and Medical Affairs. Dr. Cheng received his M.D. from Tufts University School of Medicine. He is the recipient of numerous honors and awards including the Howard Hughes Medical Institute Research Fellowship, which supported his research under Dr. Rudy Tanzi in the Genetics and Aging Unit of the Massachusetts General Hospital / Harvard Medical School. He has worked with many startups and currently sits on the Board of Directors of Traversa Therapeutics and is a board observer to Argos Therapeutics.
Mr. Mathers joined NEA as a Partner in August 2008 and is focused on biotechnology and specialty pharmaceuticals investments. He is a director of Liquidia Technologies, Ra Pharmaceuticals, Rhythm Pharmaceuticals, Envisia Therapeutics, Synlogic, Mirna Therapeutics, Lumos Pharma and Ziarco. He is also a member of NC State’s College of Sciences Foundation board. Previously he was a board member of Lumena (sold to Shire), Plexxikon (sold to Daiichi Sankyo), Intarcia, Satori Pharmaceuticals, Southeast Bio, MedImmune, LLC, and the Biotechnology Innovation Organization (BIO). Prior to joining NEA, Mr. Mathers most recently served as Executive Vice President, Corporate Development and Venture, at MedImmune, Inc. Before joining MedImmune in 2002, he was Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems. Ed spent 15 years at Glaxo Wellcome, Inc. (GlaxoSmithKline), where he held sales and marketing positions of increasing responsibility. He earned his Bachelor’s degree in chemistry from North Carolina State University.
Dr. Snyderman is Chancellor Emeritus, Duke University and James B. Duke Professor of Medicine in the Duke University School of Medicine. Dr. Snyderman served as Chancellor for Health Affairs and Dean of the School of Medicine from 1989 to July 2004. He oversaw the development of the Duke University Health System and served as its first President and Chief Executive Officer. Dr. Snyderman was a Venture Partner at New Enterprise Associates, a board member of Procter and Gamble for many years, and Senior Vice President for Medical Research and Development at Genentech, Inc. He has played a prominent role in the leadership of important national organizations such as the Association of American Physicians, the National Academy of Medicine, and the Association of American Medical Colleges, which recognized him a founder of personalized medicine. Dr. Snyderman is the recipient of numerous prestigious awards and honors as well as a major contributor to nearly 400 scientific manuscripts and numerous books.
Mr. Kirsch is a Senior Advisor for GCA Global, LLC, an investment bank. Mr. Kirsch has been focused on both M&A and Capital Markets transactions within the healthcare industry for the past 20 years. Mr. Kirsch’s experience spans advising both public and private companies with extensive knowledge of cross border transactions between the U.S. and Asia. Prior to joining GCA Global, he was a senior executive at Vector Securities responsible for the Capital Markets division. Previously, Mr. Kirsch was CEO of Natwest Markets, a leading foreign owned investment bank. Mr. Kirsch began his career on Wall Street at Drexel Burnham Lambert and eventually became head of the Equity Division and a member of the firm’s Executive Committee. He serves as Chairman of the Board of Directors at Aralez, Inc. a public biopharmaceutical company where he is also Chairman of the Audit Committee. Mr. Kirsch earned a BA in Finance at the University of Rhode Island and an MBA from Baruch College.
Mr. Rushton is currently a partner in Xeraya, a global venture capital firm that invests in the life sciences sector. From February 2011 to June 2016, Mr. Rushton was a director in the corporate finance advisory arm of Deloitte & Touche LLP. Prior to that, Mr. Rushton was an independent strategy consultant, and an investment manager at Inventages Venture Capital Investment, Inc., an investment arm of Nestle S.A. specializing in the health care and life sciences sectors. Mr. Rushton was an associate in Merlin Biosciences Fund, L.P., a venture capital firm specializing in life science companies, and a management consultant in PA Consulting Group, a global management consulting firm. Mr. Rushton started his career at Eli Lilly and Company as a biologist. Mr. Rushton holds a Bachelor of Science in Anatomy and a Master of Science in Immunology from the University of Birmingham.